DrugPatentWatch Database Preview
OZURDEX Drug Profile
see a sample report or, see our see our flat-rate plans
When do Ozurdex patents expire, and when can generic versions of Ozurdex launch?
This drug has one hundred and thirty-five patent family members in twenty-six countries.
The generic ingredient in OZURDEX is dexamethasone. There are thirty-nine drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the dexamethasone profile page.
Summary for OZURDEX
| International Patents: | 135 |
| US Patents: | 15 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 88 |
| Clinical Trials: | 59 |
| Patent Applications: | 4,647 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | OZURDEX at DailyMed |
Pharmacology for OZURDEX
| Drug Class | Corticosteroid |
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Medical Subject Heading (MeSH) Categories for OZURDEX
Synonyms for OZURDEX
| .delta.(sup 1)-9-.alpha.-Fluoro-16-.alpha.-methylcortisol |
| .gamma.corten |
| (11|A,16|A)-9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; 9|A-Fluoro-16|A-methyl-11|A,17|A,21-trihydroxy-1,4-pregnadiene-3,20-dione; 9|A-Fluoro-16|A-methylprednisolone; Prednisolone F |
| (11beta,16alpha)-9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione |
| (11beta,16alpha)-9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione labeled with tritium |
| (1R,2S,10S,11S,13R,14R,15S,17S)-1-fluoro-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,13,15-trimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-dien-5-one |
| (1R,2S,10S,11S,13R,14R,15S,17S)-1-fluoro-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,13,15-trimethyltetracyclo[8.7.0.0;{2,7}.0;{11,15}]heptadeca-3,6-dien-5-one |
| (1R,2S,10S,11S,13R,14R,15S,17S)-1-FLUORO-14,17-DIHYDROXY-14-(2-HYDROXYACETYL)-2,13,15-TRIMETHYLTETRACYCLO[8.7.0.0(2),?.0(1)(1),(1)?]HEPTADECA-3,6-DIEN-5-ONE |
| (1R,2S,10S,11S,13R,14R,15S,17S)-1-fluoro-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,13,15-trimethyltetracyclo[8.7.0.0(2),.0(1)(1),(1)]heptadeca-3,6-dien-5-one |
| (2S,10S,11S,15S,17S,1R,13R,14R)-1-fluoro-14,17-dihydroxy-14-(2-hydroxyacetyl)- 2,13,15-trimethyltetracyclo[8.7.0.0<2,7>.0<11,15>]heptadeca-3,6-dien-5-one |
| (3H)-Dexamethasone |
| (8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one |
| (8S,9R,10S,11S,13S,14S,16R,17R)-9-Fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]ph |
| (8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one |
| [3H]-dexamethasone |
| [3H]dexamethasone |
| 064D136 |
| 1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone |
| 1-Dehydro-16alpha -methyl-9alpha -fluorohydrocortisone |
| 1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone |
| 1050677-47-8 |
| 137098-19-2 |
| 16-.alpha.-Methyl-9-.alpha.-fluoro-1,17-.alpha.,21-triol-3,20-dione |
| 16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol |
| 16-alpha-Methyl-9-alpha-fluoro-1,4-pregnadiene-11-beta,17-alpha,21-triol-3,20-dione |
| 16-alpha-Methyl-9-alpha-fluoro-11-beta,17-alpha,21-trihydroxypregna-1,4-diene-3,20-dione |
| 16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone |
| 16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone |
| 16-alpha-Methyl-9-alpha-fluoroprednisolone |
| 16.alpha.-Methyl-9.alpha.-fluoro-.delta.(sup1)-hydrocortisone |
| 16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol |
| 16.alpha.-Methyl-9.alpha.-fluoro-11.beta.-17.alpha.-21-trihydroxypregna-1,20-dione |
| 16.alpha.-Methyl-9.alpha.-fluoroprednisolone |
| 16alpha -Methyl-9alpha -fluoro-1-dehydrocortisol |
| 16alpha -Methyl-9alpha -fluoroprednisolone |
| 16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol |
| 16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone |
| 16alpha-Methyl-9alpha-fluoroprednisolone |
| 1793-EP2269977A2 |
| 1793-EP2269989A1 |
| 1793-EP2269990A1 |
| 1793-EP2270008A1 |
| 1793-EP2270014A1 |
| 1793-EP2270018A1 |
| 1793-EP2272832A1 |
| 1793-EP2275420A1 |
| 1793-EP2277565A2 |
| 1793-EP2277566A2 |
| 1793-EP2277567A1 |
| 1793-EP2277568A2 |
| 1793-EP2277569A2 |
| 1793-EP2277570A2 |
| 1793-EP2277861A1 |
| 1793-EP2277865A1 |
| 1793-EP2277876A1 |
| 1793-EP2279741A2 |
| 1793-EP2281563A1 |
| 1793-EP2289894A2 |
| 1793-EP2292227A2 |
| 1793-EP2292280A1 |
| 1793-EP2292589A1 |
| 1793-EP2292614A1 |
| 1793-EP2292617A1 |
| 1793-EP2295055A2 |
| 1793-EP2295402A2 |
| 1793-EP2295409A1 |
| 1793-EP2295412A1 |
| 1793-EP2295413A1 |
| 1793-EP2295416A2 |
| 1793-EP2298731A1 |
| 1793-EP2298743A1 |
| 1793-EP2298748A2 |
| 1793-EP2298764A1 |
| 1793-EP2298765A1 |
| 1793-EP2298772A1 |
| 1793-EP2298778A1 |
| 1793-EP2298779A1 |
| 1793-EP2298780A1 |
| 1793-EP2305248A1 |
| 1793-EP2305642A2 |
| 1793-EP2305663A1 |
| 1793-EP2305689A1 |
| 1793-EP2308562A2 |
| 1793-EP2308812A2 |
| 1793-EP2308833A2 |
| 1793-EP2308839A1 |
| 1793-EP2308880A1 |
| 1793-EP2311453A1 |
| 1793-EP2314585A1 |
| 1793-EP2314590A1 |
| 1793-EP2316459A1 |
| 1793-EP2316832A1 |
| 1793-EP2316833A1 |
| 1793-EP2316834A1 |
| 1793-EP2371811A2 |
| 1p93 |
| 23495-06-9 |
| 4-alpha-Fluoro-16-alpha-methyl-11-beta,17,21-trihydroxypregna-1,4-diene-3,20-dione |
| 4.alpha.-Fluoro-16.alpha.-methyl-11.beta.-17,4-diene-3,20-dione |
| 50-02-2 |
| 7S5I7G3JQL |
| 8054-59-9 |
| 9-alpha-Fluoro-16-alpha-methyl-1,4-pregnadiene-11-beta,17-alpha,21-triol-3,20-dione |
| 9-alpha-Fluoro-16-alpha-methylprednisolone |
| 9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione |
| 9-Fluoro-11.beta.,21-trihydroxy-16.alpha.-methylpregna-1,4-diene-3,20-dione |
| 9-Fluoro-11alpha -methylpregna-1,4-diene-3,20-dione |
| 9-Fluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione |
| 9-Fluoro-16-methylprednisolone |
| 9-fluoro-16alpha-methyl-11beta,17,21-trihydroxypregna-1,4-diene-3,20-dione |
| 9.alpha.-Fluoro-11.beta.-17.alpha.- 21-trihydroxy-16.alpha.-methylpregna-1,20-dione |
| 9.alpha.-Fluoro-16.alpha.-methyl-1,20-dione |
| 9.alpha.-Fluoro-16.alpha.-methyl-11.beta.,21.beta.-trihydroxy-pregna-1,4-diene-3,20-dione |
| 9.alpha.-Fluoro-16.alpha.-methylprednisolone |
| 906362-70-7 |
| 906422-84-2 |
| 9a-Fluoro-11b,17a,21-trihydroxy-16a-methylpregna-1,4-diene-3,20-dione |
| 9A-FLUORO-16BETA-METHYLPREDNISOLONE |
| 9alpha -Fluoro-16alpha -methylprednisolone |
| 9alpha-Fluoro-16alpha-methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione |
| 9alpha-fluoro-16alpha-methyl-Prednisolone |
| 9alpha-Fluoro-16alpha-methylprednisolone |
| AB0072035 |
| AB00918428_10 |
| AB00918428-05 |
| AB00918428-08 |
| AB00918428-09 |
| AB1009273 |
| AC-11056 |
| AC1L1L1H |
| AC1Q29DM |
| ACN-036253 |
| Adexone |
| Aeroseb-D |
| Aeroseb-Dex |
| AI3-50934 |
| AJ-46415 |
| Ak Dex Oph Otic Soln 0.1% |
| AK126741 |
| AK402468 |
| AKOS005259009 |
| AKOS015895509 |
| Alcon Brand of Dexamethasone |
| alpha -Fluoro-16-alpha -methylcortisol |
| Anaflogistico |
| Aphtasolon |
| Aphthasolone |
| Apo-dexamethasone |
| ARONIS27003 |
| Auxiron |
| Azimycin (Veterinary) |
| Azium |
| Azium (Veterinary) |
| BC201625 |
| BDBM18207 |
| BIDD:ER0494 |
| BIDD:PXR0060 |
| Bisu DS |
| BRD-K38775274-001-02-3 |
| BRD-K38775274-001-06-4 |
| BSPBio_000995 |
| C15643 |
| C22H29FO5 |
| Calonat |
| CAS-50-02-2 |
| CCRIS 7067 |
| CHEBI:41879 |
| CHEMBL384467 |
| Corson |
| Corsone |
| Cortisumman |
| CS-1505 |
| D00292 |
| D0IT2G |
| DB01234 |
| Decacort |
| Decacortin |
| Decaderm |
| Decadron |
| Decadron (TN) |
| Decadron phosphate, Decdan, Dexacort, |
| Decadron Tablets, Elixir |
| Decadron-LA |
| Decadron, Dexamethasone |
| Decagel |
| Decaject |
| Decaject L.A. |
| Decaject-L.A. |
| Decalix |
| Decameth |
| Decasone |
| Decaspray |
| Dectancyl |
| Dekacort |
| delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol |
| delta1-9alpha-Fluoro-16alpha-methylcortisol |
| Deltafluorene |
| Dergramin |
| Deronil |
| Desadrene |
| Desametasone |
| Desametasone [DCIT] |
| Desamethasone |
| Desameton |
| Deseronil |
| Dex-ide |
| Dexa Mamallet |
| Dexa-Cortidelt |
| Dexa-Cortisyl |
| Dexa-Mamallet |
| Dexa-Scheroson |
| Dexa-sine |
| Dexacen-4 |
| Dexacidin |
| Dexacort |
| Dexacortal |
| Dexacortin |
| Dexadeltone |
| Dexafarma |
| Dexair |
| Dexalona |
| Dexaltin |
| Dexametasona |
| Dexametasona [INN-Spanish] |
| Dexametasone |
| Dexameth |
| Dexamethansone |
| dexamethasone |
| Dexamethasone Cyclodextrin complex |
| Dexamethasone (DHAP) |
| Dexamethasone (JP15/USP/INN) |
| Dexamethasone (JP17/USP/INN) |
| dexamethasone (tetramethyl-rhodamine conjugated ) |
| Dexamethasone [INN:BAN:JAN] |
| Dexamethasone [USP:INN:BAN:JAN] |
| Dexamethasone 1.0 mg/ml in Methanol |
| Dexamethasone alcohol |
| Dexamethasone Base |
| Dexamethasone for peak identification, European Pharmacopoeia (EP) Reference Standard |
| Dexamethasone for system suitability, European Pharmacopoeia (EP) Reference Standard |
| Dexamethasone Intensol |
| Dexamethasone solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material |
| Dexamethasone-omega |
| Dexamethasone, >=97.0% (HPLC) |
| Dexamethasone, >=98% (HPLC), powder |
| Dexamethasone, 98% 1g |
| Dexamethasone, European Pharmacopoeia (EP) Reference Standard |
| Dexamethasone, meets USP testing specifications |
| Dexamethasone, pharmaceutical secondary standard; traceable to USP, PhEur, BP |
| Dexamethasone, powder, BioReagent, suitable for cell culture, >=97% |
| Dexamethasone, powder, gamma-irradiated, BioXtra, suitable for cell culture, >=80% (HPLC) |
| Dexamethasone, tested according to Ph.Eur. |
| Dexamethasone, United States Pharmacopeia (USP) Reference Standard |
| Dexamethasone, VETRANAL(TM), analytical standard |
| Dexamethasonum |
| Dexamethasonum [INN-Latin] |
| Dexamethazone |
| Dexamonozon |
| Dexapolcort |
| Dexapos |
| Dexaprol |
| DexaSite |
| Dexason |
| Dexasone |
| Dexasone 0.5mg |
| Dexasone 0.75mg |
| Dexasone 4mg |
| Dexinolon |
| Dexinoral |
| dexmethsone |
| Dexone |
| Dexone 0.5 |
| Dexone 0.75 |
| Dexone 1.5 |
| Dexone 4 |
| Dexonium |
| Dexpak |
| Dextelan |
| Dextenza |
| Dezone |
| Dinormon |
| DSSTox_CID_384 |
| DSSTox_GSID_20384 |
| DSSTox_RID_75557 |
| DTXSID3020384 |
| DXM |
| DXM [Steroid] |
| Dxms |
| ECR Brand of Dexamethasone |
| EINECS 200-003-9 |
| EN300-52607 |
| Fluormethylprednisolone |
| Fluormone |
| Fluorocort |
| Fortecortin |
| Foy Brand of Dexamethasone |
| FT-0080377 |
| FT-0601576 |
| FT-0603100 |
| Gammacorten |
| GTPL2768 |
| GTPL3447 |
| Hexadecadrol |
| Hexadrol |
| Hexadrol Elixir |
| Hexadrol Tablets |
| Hl-dex |
| HMS1792A17 |
| HMS1990A17 |
| HMS2089N13 |
| HMS2235F08 |
| HMS3039L11 |
| HMS3259N11 |
| HMS3403A17 |
| HSDB 3053 |
| HY-14648 |
| I06-1196 |
| IBI-10090 |
| ICN Brand of Dexamethasone |
| IontoDex |
| Isopto-Dex |
| ISV-305 |
| J10029 |
| KS-000048I3 |
| KS-1451 |
| Lokalison F |
| Loverine |
| LS-7300 |
| Luxazone |
| Maxidex |
| Maxidex Ont 0.1% |
| Maxidex Sus 0.1% |
| Maxitrol |
| MCULE-4773827191 |
| Mediamethasone |
| Merck Brand of Dexamethasone |
| Merz Brand 1 of Dexamethasone |
| Merz Brand 2 of Dexamethasone |
| Methylfluorprednisolone |
| Mexidex |
| MFCD00064136 |
| Millicorten |
| MK 125 |
| MLS001055412 |
| MLS001332507 |
| MLS001332508 |
| MolMap_000018 |
| MolPort-003-846-433 |
| Mymethasone |
| Naquasone (Veterinary) |
| NC00645 |
| NCGC00091019-01 |
| NCGC00091019-02 |
| NCGC00091019-03 |
| NCGC00091019-04 |
| NCGC00091019-05 |
| NCGC00091019-06 |
| NCGC00091019-07 |
| NCGC00091019-08 |
| NCGC00257676-01 |
| NCI60_003067 |
| Neomycin and polymyxin b sulphates and dexamethasone |
| NSC 34521 |
| NSC-34521 |
| NSC34521 |
| Ocu-trol |
| Oradexon |
| Osurdex |
| OTO-104 |
| Pet Derm III |
| Pet-Derm Iii |
| PHL-dexamethasone |
| PL007868 |
| PMS Dexamethasone Elixir 0.5mg/5ml |
| PMS-dexamethasone |
| Policort |
| Posurdex |
| Prednisolon F |
| Prednisolone F |
| Prednisolone, 9.alpha.-fluoro-16.alpha.-methyl- |
| Prednisolone, 9alpha -fluoro-16alpha -methyl- |
| Prednisolone, 9alpha-fluoro-16alpha-methyl- |
| Pregna-1,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11.beta.,16.alpha.)- |
| Pregna-1,20-dione, 9-fluoro-11.beta.,17,21-trihydroxy-16.alpha.-methyl- |
| Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11.beta.,16.alpha.)- |
| Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11beta,16alpha)- |
| Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, labeled with tritium, (11beta,16alpha)- |
| Pregna-1,4-diene-3,20-dione, 9-fluoro-11alpha -methyl- |
| Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,17,21-trihydroxy-16alpha-methyl- |
| Prodex |
| Q-200939 |
| s1322 |
| Sandoz Dexamethasone |
| SC-16127 |
| SCHEMBL3774 |
| SGCUT00126 |
| SK-Dexamethasone |
| SMP1_000092 |
| SMR000857119 |
| SMR001227192 |
| Spectrum5_002019 |
| Spoloven |
| ST24046431 |
| ST50307091 |
| Sunia Sol D |
| Superprednol |
| sustained-release dexamethasone |
| TL8003317 |
| to_000038 |
| Tox21_200122 |
| Tresaderm (Veterinary) |
| Turbinaire |
| UNII-7S5I7G3JQL |
| UREBDLICKHMUKA-CXSFZGCWSA-N |
| Visumetazone |
| W-5058 |
| WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ G1 |
| Z802671480 |
| ZINC3875332 |
US Patents and Regulatory Information for OZURDEX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allergan | OZURDEX | dexamethasone | IMPLANT;INTRAVITREAL | 022315-001 | Jun 17, 2009 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Allergan | OZURDEX | dexamethasone | IMPLANT;INTRAVITREAL | 022315-001 | Jun 17, 2009 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Allergan | OZURDEX | dexamethasone | IMPLANT;INTRAVITREAL | 022315-001 | Jun 17, 2009 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Allergan | OZURDEX | dexamethasone | IMPLANT;INTRAVITREAL | 022315-001 | Jun 17, 2009 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
see a sample report or, see our see our flat-rate plans
Non-Orange Book US Patents for OZURDEX
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 7,468,065 | Apparatus for delivery of ocular implants | ➤ Sign Up |
| 6,699,493 | Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor | ➤ Sign Up |
| 8,242,099 | Implants and methods for treating inflammation-mediated conditions of the eye | ➤ Sign Up |
| 7,147,644 | Apparatus for delivery of ocular implants | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
see a sample report or, see our see our flat-rate plans
International Patents for OZURDEX
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Spain | 2297766 | ➤ Sign Up |
| World Intellectual Property Organization (WIPO) | 2006071554 | ➤ Sign Up |
| Norway | 20080055 | ➤ Sign Up |
| Japan | 4223040 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for OZURDEX
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| C0012 | France | ➤ Sign Up | PRODUCT NAME: COMBINAISON DE CIPROFLOXACINE ET DE DEXAMETHASONE, EN PARTICULIER DE CHLORHYDRATE DE CIPROFLOXACINE ET DE DEXAMETHASONE; NAT. REGISTRATION NO/DATE: NL 41308 20121214; FIRST REGISTRATION: 48976 20120808 |
| C/GB12/047 | United Kingdom | ➤ Sign Up | PRODUCT NAME: DEXAMETHASONE; REGISTERED: UK EU/1/10/638/001 20100727 |
| 2012000081 | Germany | ➤ Sign Up | PRODUCT NAME: DEXAMETHASON; REGISTRATION NO/DATE: EU/1/10/638/001 20100727 |
| C/GB12/058 | United Kingdom | ➤ Sign Up | PRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
